SomnoMed Upgrades Fiscal 2025 Revenue, EBITDA Guidance; Shares Soar 41%

MT Newswires Live

Nov 27, 2024

SomnoMed (ASX:SOM) upgraded its revenue guidance for fiscal 2025 to roughly AU$105 million from AU$100 million, according to a Wednesday filing with the Australian bourse.

It also revised its earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance to more than AU$7 million, up from a prior outlook of AU$5 million.

In the same filing, the company said it appointed Ye-Fei Guo as chief financial officer, effective immediately.

The company, which develops treatment products for sleep-related breathing disorders, saw shares climb almost 41% in afternoon trade Wednesday.

Price (AUD): $0.38, Change: $+0.11, Percent Change: +40.74%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2486962048"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486962048\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2486962048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 12:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486962048","market":"sg","top_or_hot":-1,"title":"SomnoMed Upgrades Fiscal 2025 Revenue, EBITDA Guidance; Shares Soar 41%","media":"MT Newswires Live","content":"<html><body><p> SomnoMed (ASX:SOM) upgraded its revenue guidance for fiscal 2025 to roughly AU$105 million from AU$100 million, according to a Wednesday filing with the Australian bourse.</p><p>It also revised its earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance to more than AU$7 million, up from a prior outlook of AU$5 million.</p><p>In the same filing, the company said it appointed Ye-Fei Guo as chief financial officer, effective immediately.</p><p>The company, which develops treatment products for sleep-related breathing disorders, saw shares climb almost 41% in afternoon trade Wednesday.</p><p>Price (AUD): $0.38, Change: $+0.11, Percent Change: +40.74%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SomnoMed Upgrades Fiscal 2025 Revenue, EBITDA Guidance; Shares Soar 41%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSomnoMed Upgrades Fiscal 2025 Revenue, EBITDA Guidance; Shares Soar 41%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-27 12:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> SomnoMed (ASX:SOM) upgraded its revenue guidance for fiscal 2025 to roughly AU$105 million from AU$100 million, according to a Wednesday filing with the Australian bourse.</p><p>It also revised its earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance to more than AU$7 million, up from a prior outlook of AU$5 million.</p><p>In the same filing, the company said it appointed Ye-Fei Guo as chief financial officer, effective immediately.</p><p>The company, which develops treatment products for sleep-related breathing disorders, saw shares climb almost 41% in afternoon trade Wednesday.</p><p>Price (AUD): $0.38, Change: $+0.11, Percent Change: +40.74%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SOM.AU","symbol_name":"SOMNOMED LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486962048","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486962048","pubTimestamp":1732683507,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SomnoMed  upgraded its revenue guidance for fiscal 2025 to roughly AU$105 million from AU$100 million, according to a Wednesday filing with the Australian bourse.It also revised its earnings before interest, taxes, depreciation, and amortization  guidance to more than AU$7 million, up from a prior outlook of AU$5 million.In the same filing, the company said it appointed Ye-Fei Guo as chief financial officer, effective immediately.The company, which develops treatment products for sleep-related breathing disorders, saw shares climb almost 41% in afternoon trade Wednesday.Price : $0.38, Change: $+0.11, Percent Change: +40.74%","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"SOM.AU":"SOMNOMED LTD"},"translate_title":"SomnoMed上调2025财年收入、EBITDA指引；股价飙升41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOM.AU":0.9},"content_text":"SomnoMed (ASX:SOM) upgraded its revenue guidance for fiscal 2025 to roughly AU$105 million from AU$100 million, according to a Wednesday filing with the Australian bourse.It also revised its earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance to more than AU$7 million, up from a prior outlook of AU$5 million.In the same filing, the company said it appointed Ye-Fei Guo as chief financial officer, effective immediately.The company, which develops treatment products for sleep-related breathing disorders, saw shares climb almost 41% in afternoon trade Wednesday.Price (AUD): $0.38, Change: $+0.11, Percent Change: +40.74%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}